IBRX280121C00005000
IBRX Jan 21 2028 5.00 Call
optionOPRA
EODOct 16, 2026
5.44USD-11.545%(-0.71)4,002Vol12,523OI
Loading…
Underlying
Underlying Price
$8.48
Type
Call
Strike
5
Expiration
Jan 21, 2028
DTE
458d
Moneyness
ITM
Intrinsic
$3.48
IBRX 5 Call Across Expirations
| Expiration | DTE | Last | Change | Vol | Open Int |
|---|---|---|---|---|---|
| Oct 23, 2026 | 3d | $5.10 | +82.14% | 1 | 1 |
| Oct 30, 2026 | 10d | $5.80 | +62.01% | 1 | 1 |
| Nov 6, 2026 | 17d | $4.95 | +0.00% | 2 | 1 |
| Nov 13, 2026 | 24d | — | — | 0 | 0 |
| Nov 20, 2026 | 31d | $4.85 | -6.73% | 4 | 3 |
| Nov 27, 2026 | 38d | — | — | 0 | 0 |
| Dec 18, 2026 | 59d | — | — | 0 | 0 |
| Jan 15, 2027 | 87d | $4.40 | -16.98% | 41 | 26,601 |
| Mar 19, 2027 | 150d | $5.40 | +0.93% | 15 | 350 |
| Apr 16, 2027 | 178d | $5.70 | +9.62% | 2 | 25 |
| May 21, 2027 | 213d | $5.58 | +4.30% | 2 | 55 |
| Aug 20, 2027 | 304d | $5.30 | -11.67% | 5 | 26 |
| Nov 19, 2027 | 395d | $5.25 | -9.95% | 7 | 68 |
| Jan 21, 2028 | 458d | $5.44 | -11.54% | 4,002 | 12,523 |
| Mar 17, 2028 | 514d | $5.90 | -3.28% | 5 | 373 |
| Jan 19, 2029 | 822d | $6.40 | -4.48% | 15 | 234 |
IBRX Nearby Strikes · Jan 21, 2028
| Strike | Last | Change | Vol | Open Int | Moneyness |
|---|---|---|---|---|---|
| 2 C | $7.90 | -10.63% | 4 | 5,401 | ITM |
| 2.5 C | $7.40 | -7.50% | 6 | 15,793 | ITM |
| 3 C | $6.50 | -16.13% | 1 | 31,197 | ITM |
| 3.5 C | $7.10 | +1.87% | 10 | 27,275 | ITM |
| 4 C | $6.75 | -1.75% | 15 | 2,170 | ITM |
| 4.5 C | $6.65 | +2.78% | 2 | 380 | ITM |
| 5 C | $5.44 | -11.54% | 4,002 | 12,523 | ITM |
| 5.5 C | $5.21 | -12.14% | 2 | 3,508 | ITM |
| 7.5 C | $4.20 | -10.64% | 9,831 | 18,015 | ITM |
| 10 C | $3.20 | -14.44% | 677 | 10,691 | OTM |
| 12 C | $2.70 | -20.59% | 16 | 1,740 | OTM |
| 15 C | $2.80 | +3.70% | 53 | 7,866 | OTM |
| 17 C | $2.82 | +4.44% | 30 | 1,006 | OTM |
IBRX Profile
immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.